U.S. markets open in 1 hour 31 minutes
  • S&P Futures

    4,419.25
    -18.75 (-0.42%)
     
  • Dow Futures

    34,526.00
    -118.00 (-0.34%)
     
  • Nasdaq Futures

    15,213.75
    -89.75 (-0.59%)
     
  • Russell 2000 Futures

    2,244.30
    -10.90 (-0.48%)
     
  • Crude Oil

    73.16
    -0.14 (-0.19%)
     
  • Gold

    1,752.30
    +2.50 (+0.14%)
     
  • Silver

    22.58
    -0.06 (-0.25%)
     
  • EUR/USD

    1.1718
    -0.0029 (-0.25%)
     
  • 10-Yr Bond

    1.4100
    0.0000 (0.00%)
     
  • Vix

    19.94
    -0.93 (-4.46%)
     
  • GBP/USD

    1.3676
    -0.0045 (-0.33%)
     
  • USD/JPY

    110.5350
    +0.2340 (+0.21%)
     
  • BTC-USD

    41,563.57
    -2,071.84 (-4.75%)
     
  • CMC Crypto 200

    1,032.67
    -76.25 (-6.88%)
     
  • FTSE 100

    7,063.46
    -14.89 (-0.21%)
     
  • Nikkei 225

    30,248.81
    +609.41 (+2.06%)
     

Cassava Sciences Seeks $200M From Equity Offering At 15% Discount To Fund Development Of Lead Candidate

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Cassava Sciences Inc (NASDAQ: SAVA) has entered into a definitive agreement with several institutional investors for the purchase of 4.1 million common shares at per share, for gross proceeds of approximately $200 million, in a registered direct offering. The offer price is at a 15% discount from the last close price of $57.56 on Tuesday.

  • H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering and is expected to close by February 12.

  • Cassava Sciences intends to use the net proceeds to develop simufilam, its lead drug candidate for Alzheimer's disease.

  • Earlier this week, shares rallied after the company announced expanding the size of the ongoing simufilam open-label study and its plans to initiate a six-month study in patients who complete at least one year of open-label treatment with simufilam.

  • Price Action: SAVA dropped 12.7% at $50.27 during premarket trading hours on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.